-
Mamdani-backed leftist candidates win New York Democratic primaries
-
Hantavirus outbreak should formally end on July 2: WHO
-
Britain's Draper continues promising start under Andy Murray
-
Hong Kong arrests two for allegedly selling 'seditious' material
-
Laporte wary of Uruguay will to avoid World Cup exit against Spain
-
US promises to protect Gulf states' interests in Iran talks
-
Major Nigeria police reform edges forward with senate approval
-
Trials of two Ebola treatments to start in DRC next week: WHO
-
Trump consolidates rightward shift in Latin America
-
Judge asks why Kennedy Center covering facade after Trump's name removed
-
Olympics to offer all Games competitors $10,000 grants
-
Germany sinks troubled warship project in blow to naval ambitions
-
Left-wing candidate concedes tight Colombia election
-
US health deals cause trouble for Kenya govt
-
Stocks rebound after tech rout, Brent falls below $75
-
Socialism with a twist or crony capitalism? Cuban reforms spark debate
-
Berlin unveils monument to Jehovah's Witnesses murdered by Nazis
-
'Inhumane': Gaza flotilla activists recount Israeli detention ordeal
-
'Fingerprints' of black hole's event horizon detected for first time
-
Spurs sign Dubravka as goalkeeper cover
-
Verstappen seeking home boost with Red Bull upgrades
-
Stocks steady after tech rout, Brent falls below $75
-
'You have to work': Riders brave Rome heat for survival
-
England captain Stokes 'man enough' to apologise for curfew breach
-
France detects first Ebola case outside Africa in current outbreak
-
England captain Stokes 'man enough' to apologise after curfew breach
-
'GTA VI' preorders mark first test for biggest game of 2026
-
German naval ambitions suffer setback as warship order axed
-
Stocks rebound after tech rout, oil prices drop
-
London police to extend use of live facial recognition, drones
-
Australia spy chief warns of Iran terror threat
-
Europe swelters under record-breaking heatwave
-
Heatwave-hit Europe must adapt healthcare: WHO
-
Iran says deal to end Mideast war 'declaration of US defeat'
-
Euclid telescope snaps best photo yet of Milky Way's heart
-
S.Korea chip giant SK hynix seeks $29 bn in Nasdaq listing: regulatory filing
-
French-German tank maker KNDS fires starting gun on mega-IPO
-
'Pragmatists' vs 'hardliners': Is Iran split over US deal?
-
Right-winger Fujimori poised to win Peru president runoff
-
H5 bird flu detected in second Australia state
-
Major power outage in France as Europe wilts under record heat
-
Brazil aim for last 32 as World Cup goes into hectic phase
-
Back in stork: returning birds bring joy to Croatian village
-
Necessity drives gold miners in DR Congo's Ebola epicentre
-
China premier urges AI governance to avoid 'losing control'
-
Japan PM heckled at WWII memorial
-
Colombia beat DR Congo 1-0 to reach World Cup knockouts
-
Hanoi residents mount silent protest over home demolitions
-
West Indies brace for Sri Lanka challenge as Da Silva returns
-
US Congress passes symbolic Iran war rebuke to Trump
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, announced today that Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat moderated by Thomas Flaten, Senior Research Analyst at Lake Street Capital Markets, at the Lytham Partners 2026 Investor Healthcare Summit.
The webcast will take place at 5:00 p.m. Eastern time on Thursday, January 15, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/hc2026/ or directly at https://lythampartners.com/hc2026/aytu. A replay will also be available through the same links.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
A.Clark--AT